S&P 500   3,313.72 (-0.24%)
DOW   29,059.52 (-0.43%)
QQQ   223.98 (+0.05%)
AAPL   317.93 (+0.07%)
FB   220.11 (-0.55%)
MSFT   166.15 (+0.27%)
GOOGL   1,486.12 (+0.13%)
AMZN   1,881.07 (-0.34%)
CGC   24.37 (+1.04%)
NVDA   251.69 (+0.66%)
BABA   218.05 (-1.94%)
MU   59.52 (+0.59%)
GE   11.73 (+3.17%)
TSLA   566.21 (-0.59%)
AMD   51.29 (-0.27%)
T   38.63 (-1.05%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.88 (+5.48%)
BAC   33.92 (-1.28%)
GILD   63.06 (-0.58%)
S&P 500   3,313.72 (-0.24%)
DOW   29,059.52 (-0.43%)
QQQ   223.98 (+0.05%)
AAPL   317.93 (+0.07%)
FB   220.11 (-0.55%)
MSFT   166.15 (+0.27%)
GOOGL   1,486.12 (+0.13%)
AMZN   1,881.07 (-0.34%)
CGC   24.37 (+1.04%)
NVDA   251.69 (+0.66%)
BABA   218.05 (-1.94%)
MU   59.52 (+0.59%)
GE   11.73 (+3.17%)
TSLA   566.21 (-0.59%)
AMD   51.29 (-0.27%)
T   38.63 (-1.05%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.88 (+5.48%)
BAC   33.92 (-1.28%)
GILD   63.06 (-0.58%)
S&P 500   3,313.72 (-0.24%)
DOW   29,059.52 (-0.43%)
QQQ   223.98 (+0.05%)
AAPL   317.93 (+0.07%)
FB   220.11 (-0.55%)
MSFT   166.15 (+0.27%)
GOOGL   1,486.12 (+0.13%)
AMZN   1,881.07 (-0.34%)
CGC   24.37 (+1.04%)
NVDA   251.69 (+0.66%)
BABA   218.05 (-1.94%)
MU   59.52 (+0.59%)
GE   11.73 (+3.17%)
TSLA   566.21 (-0.59%)
AMD   51.29 (-0.27%)
T   38.63 (-1.05%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.88 (+5.48%)
BAC   33.92 (-1.28%)
GILD   63.06 (-0.58%)
S&P 500   3,313.72 (-0.24%)
DOW   29,059.52 (-0.43%)
QQQ   223.98 (+0.05%)
AAPL   317.93 (+0.07%)
FB   220.11 (-0.55%)
MSFT   166.15 (+0.27%)
GOOGL   1,486.12 (+0.13%)
AMZN   1,881.07 (-0.34%)
CGC   24.37 (+1.04%)
NVDA   251.69 (+0.66%)
BABA   218.05 (-1.94%)
MU   59.52 (+0.59%)
GE   11.73 (+3.17%)
TSLA   566.21 (-0.59%)
AMD   51.29 (-0.27%)
T   38.63 (-1.05%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.88 (+5.48%)
BAC   33.92 (-1.28%)
GILD   63.06 (-0.58%)
Log in
(Ad)
In my 40+ year career, I have yet to see a convergence of three significant factors that has me this optimistic about the stock market. I believe 2020 could deliver the largest wealth-building opportunity in a generation. Don't miss out on this historic year.

NASDAQ:OREX - Orexigen Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.22
MA: $0.22
$0.22
52-Week Range N/A
Volume3.74 million shs
Average Volume1.16 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orexigen Therapeutics, Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc was founded in 2002 and is headquartered in La Jolla, California. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive OREX News and Ratings via Email

Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating the Zacks' consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to analyst estimates of $24.20 million. Orexigen Therapeutics's quarterly revenue was up 170.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.12 earnings per share. View Orexigen Therapeutics' Earnings History.

Has Orexigen Therapeutics been receiving favorable news coverage?

Media stories about OREX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Orexigen Therapeutics earned a news sentiment score of -3.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Orexigen Therapeutics.

Who are some of Orexigen Therapeutics' key competitors?

What other stocks do shareholders of Orexigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), ImmunoGen (IMGN), MannKind (MNKD), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Opko Health (OPK), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP) and Biogen (BIIB).

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the folowing people:
  • Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
  • Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
  • Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
  • Ms. Monica Forbes, VP & Acting CFO (Age 42)
  • Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)

What is Orexigen Therapeutics' official website?

The official website for Orexigen Therapeutics is http://www.orexigen.com/.

How can I contact Orexigen Therapeutics?

Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]


MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Cryptocurrencies

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel